Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Elewaut

Showing results (21-30 of 299) with videos related to

Pageof 30
Sort By:
Expert Opinion on Drug Discovery|March 20, 2013
Entering the era of proteomics in rheumatologyStijn Lambrecht, Dieter Deforce, Dirk Elewaut
Journal of Visualized Experiments : Jove|November 12, 2015
An Optimized Method for Isolating and Expanding Invariant Natural Killer T Cells from Mouse SpleenSrinath Govindarajan, Dirk Elewaut, Michael Drennan
Rheumatology (Oxford, England)|December 15, 2012
Should we be morbid about comorbidities in the rheumatic diseases?Dirk Elewaut, Nicola Goodson, Roy Fleischmann
Current Opinion in Rheumatology|May 21, 2010
Interactions between gut inflammation and arthritis/spondylitisPeggy Jacques, Dirk Elewaut, Herman Mielants
Rheumatology (Oxford, England)|October 14, 2011
Safe and well toleratedRoy Fleischmann, Nicola Goodson, Dirk Elewaut
Nature Reviews. Rheumatology|November 21, 2012
Spondyloarthritis: A conundrum: classifying patients with SpA in daily practiceFilip Van den Bosch, Dirk Elewaut
Arthritis and Rheumatism|February 23, 2012
Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammationWalter P Maksymowych, Dirk Elewaut, Georg Schett
Annals of the Rheumatic Diseases|July 31, 2016
MAIT cells: not just another brick in the wallKarlijn Debusschere, Rik J Lories, Dirk Elewaut
Annals of the Rheumatic Diseases|July 23, 2015
Spreading spondyloarthritis: are ILCs cytokine shuttles from base camp gut?Barbara Neerinckx, Dirk Elewaut, Rik J Lories
Nature Reviews. Rheumatology|February 4, 2010
Invariant natural killer T cells in rheumatic disease: a joint dilemmaMichael B Drennan, Sandrine Aspeslagh, Dirk Elewaut
Pageof 30

Showing results (21-30 of 299) with videos related to

Sort By:
Pageof 30
Expert Opinion on Drug Discovery|March 20, 2013
Entering the era of proteomics in rheumatologyStijn Lambrecht, Dieter Deforce, Dirk Elewaut
Journal of Visualized Experiments : Jove|November 12, 2015
An Optimized Method for Isolating and Expanding Invariant Natural Killer T Cells from Mouse SpleenSrinath Govindarajan, Dirk Elewaut, Michael Drennan
Rheumatology (Oxford, England)|December 15, 2012
Should we be morbid about comorbidities in the rheumatic diseases?Dirk Elewaut, Nicola Goodson, Roy Fleischmann
Current Opinion in Rheumatology|May 21, 2010
Interactions between gut inflammation and arthritis/spondylitisPeggy Jacques, Dirk Elewaut, Herman Mielants
Rheumatology (Oxford, England)|October 14, 2011
Safe and well toleratedRoy Fleischmann, Nicola Goodson, Dirk Elewaut
Nature Reviews. Rheumatology|November 21, 2012
Spondyloarthritis: A conundrum: classifying patients with SpA in daily practiceFilip Van den Bosch, Dirk Elewaut
Arthritis and Rheumatism|February 23, 2012
Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammationWalter P Maksymowych, Dirk Elewaut, Georg Schett
Annals of the Rheumatic Diseases|July 31, 2016
MAIT cells: not just another brick in the wallKarlijn Debusschere, Rik J Lories, Dirk Elewaut
Annals of the Rheumatic Diseases|July 23, 2015
Spreading spondyloarthritis: are ILCs cytokine shuttles from base camp gut?Barbara Neerinckx, Dirk Elewaut, Rik J Lories
Nature Reviews. Rheumatology|February 4, 2010
Invariant natural killer T cells in rheumatic disease: a joint dilemmaMichael B Drennan, Sandrine Aspeslagh, Dirk Elewaut
Pageof 30